{"log_id": 241298122309189633, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 1e-06, "average": 0.999267, "min": 0.996653}, "location": {"width": 223, "top": 135, "height": 30, "left": 110}, "words": "特别关注的不良反应"}, {"probability": {"variance": 0.006731, "average": 0.978887, "min": 0.53891}, "location": {"width": 943, "top": 195, "height": 32, "left": 160}, "words": "血压升高:在阿帕替尼治疗胃癌的Ⅲ1期临床研究中,试验组共62例(35.23%)患者出现"}, {"probability": {"variance": 0.003475, "average": 0.989869, "min": 0.621778}, "location": {"width": 977, "top": 251, "height": 31, "left": 110}, "words": "血压升高,其中8例为3级血压升高,未发生4级血压升高:安慰剂组有5例出现血压升高"}, {"probability": {"variance": 0.004407, "average": 0.98214, "min": 0.56962}, "location": {"width": 969, "top": 305, "height": 30, "left": 122}, "words": "(5.49%),均为1/2级,无3/4级血压升高发生,两组均未出现高血压危象。发生血压升高"}, {"probability": {"variance": 3e-05, "average": 0.997832, "min": 0.970555}, "location": {"width": 989, "top": 358, "height": 32, "left": 111}, "words": "的患者大多在服药后2周左右发生,多数患者一般可通过合并使用降压药使血压升高得到良好"}, {"probability": {"variance": 0, "average": 0.999456, "min": 0.998941}, "location": {"width": 53, "top": 415, "height": 28, "left": 109}, "words": "控制"}, {"probability": {"variance": 0.002013, "average": 0.985071, "min": 0.790983}, "location": {"width": 945, "top": 474, "height": 31, "left": 158}, "words": "蛋白尿:在Ⅲ1期临床研究中,试验组共78例患者(44.32%)出现蛋白尿,其中4例为3"}, {"probability": {"variance": 0.000638, "average": 0.990439, "min": 0.859248}, "location": {"width": 993, "top": 523, "height": 31, "left": 110}, "words": "级,未发生4级蛋白尿;安慰剂组共15例患者(16.48%)出现蛋白尿,均为12级,无3/4"}, {"probability": {"variance": 0.001921, "average": 0.987946, "min": 0.733449}, "location": {"width": 928, "top": 572, "height": 32, "left": 109}, "words": "级蛋白尿发生。蛋白尿一般在服药后3周左右发生,可通过暂停给药或剂量下调而缓解"}, {"probability": {"variance": 0.000106, "average": 0.996653, "min": 0.933182}, "location": {"width": 943, "top": 630, "height": 32, "left": 157}, "words": "手足综合征在Ⅲ期临床研究中,试验组共49例患者(27.84%)发生手足综合征,其中"}, {"probability": {"variance": 0.000203, "average": 0.993566, "min": 0.922904}, "location": {"width": 971, "top": 683, "height": 31, "left": 117}, "words": "15例为3级未发生4级手足综合征。安慰剂组有1例患者(1.10%)发生2级手足综合征"}, {"probability": {"variance": 0.010753, "average": 0.966588, "min": 0.480977}, "location": {"width": 588, "top": 737, "height": 34, "left": 110}, "words": "手足综合征多在服药后3周左者发生,对症治疗可减轻"}, {"probability": {"variance": 0.000458, "average": 0.994194, "min": 0.869222}, "location": {"width": 929, "top": 792, "height": 29, "left": 158}, "words": "出血:在Ⅲ期临床研究中,观察到的出血症状包括消化道出血、呕血、咯血、大便潜血"}, {"probability": {"variance": 0.004927, "average": 0.984285, "min": 0.559979}, "location": {"width": 975, "top": 847, "height": 31, "left": 109}, "words": "尿潜血、皮肤出血点、肝转移灶破裂大出血等。试验组与对照组出血的发生率分别为19.89%"}, {"probability": {"variance": 0.002601, "average": 0.983611, "min": 0.733983}, "location": {"width": 982, "top": 900, "height": 30, "left": 117}, "words": "4.18%,中重度出血发生率分别为3.41%、7.69%。发生大便潜血的患者一般在服药后第1周"}, {"probability": {"variance": 1e-06, "average": 0.998603, "min": 0.996613}, "location": {"width": 96, "top": 958, "height": 28, "left": 111}, "words": "期内发生"}, {"probability": {"variance": 0.001203, "average": 0.988161, "min": 0.812041}, "location": {"width": 931, "top": 1008, "height": 31, "left": 158}, "words": "心脏毒性:在Ⅲ期临床研究中,试验组和安慰剂组分别发生5例(2.84%)和1例(1.10%)"}, {"probability": {"variance": 0.00102, "average": 0.99368, "min": 0.789561}, "location": {"width": 980, "top": 1060, "height": 36, "left": 111}, "words": "心电图异常,包括窦性心动过缓、部分ST-T改变、心率减慢、QT间期延长、急性心肌梗塞"}, {"probability": {"variance": 0, "average": 0.999733, "min": 0.999733}, "location": {"width": 29, "top": 1121, "height": 27, "left": 111}, "words": "等"}, {"probability": {"variance": 0.005728, "average": 0.98047, "min": 0.634376}, "location": {"width": 924, "top": 1169, "height": 34, "left": 158}, "words": "肝脏毒性:在I期临床研究中,肝脏毒性包括服药后转氨酶、胆红素、碱性磷酸酶、y"}, {"probability": {"variance": 0.000184, "average": 0.995052, "min": 0.917968}, "location": {"width": 991, "top": 1224, "height": 34, "left": 112}, "words": "谷氨酰转肽酶、乳酸脱氢酶升高等,试验组与安慰剂组发生情况无显著差别。肝酶异常多数在"}, {"probability": {"variance": 1e-06, "average": 0.999272, "min": 0.996558}, "location": {"width": 294, "top": 1282, "height": 30, "left": 112}, "words": "服药后第2周期开始时发生"}, {"probability": {"variance": 0.001486, "average": 0.97229, "min": 0.905685}, "location": {"width": 86, "top": 1326, "height": 29, "left": 118}, "words": "【禁忌】"}, {"probability": {"variance": 4e-06, "average": 0.99904, "min": 0.98825}, "location": {"width": 931, "top": 1380, "height": 38, "left": 170}, "words": "对本品任何成份过敏者应禁用;对于有活动性出血、溃疡、肠穿孔、肠梗阻、大手术后"}, {"probability": {"variance": 0.000367, "average": 0.993967, "min": 0.873599}, "location": {"width": 990, "top": 1435, "height": 38, "left": 119}, "words": "30天内、药物不可控制的高血压、ⅢⅣ级心功能不全(NYHA标准)、重度肝肾功能不全(4"}, {"probability": {"variance": 7e-06, "average": 0.997736, "min": 0.99178}, "location": {"width": 171, "top": 1498, "height": 29, "left": 112}, "words": "级)患者应禁用"}], "language": 3}